This Market Spotlight report covers the Peripheral T-Cell Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
Published: 09 August 2021
Number of pages:35
This Market Spotlight report covers the Peripheral T-Cell Lymphoma (PTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2017, there were approximately 19,950 incident cases of peripheral T-cell lymphoma (PTCL) worldwide, and forecasts that number to increase to 23,880 incident cases by 2026.
It is estimated that the majority of diagnosed cases were in males in 2017.
The incidence of PTCL is highest among older individuals aged 60+ years. The approved drugs in the PTCL space focus on a wide variety of targets. These drugs are administered via the intravenous and oral routes.
All industry-sponsored drugs in active clinical development for PTCL are in Phase II, except for a single product in Phase I. Therapies in development for PTCL focus on a wide variety of targets. These therapies are administered via the oral and intravenous routes.
The only high-impact upcoming event for drugs in the PTCL space is an estimated supplemental CHMP opinion for Adcetris. The overall likelihood of approval of a Phase I hematologic asset is 8.5%, and the average probability a drug advances from Phase III is 58.4%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for PTCL have been in the early and mid-phases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
The US has a substantial lead in the number of PTCL clinical trials globally. France, Italy, and the UK lead the major European markets, while China has the top spot in Asia.
Bristol Myers Squibb has the highest number of ongoing clinical trials for PTCL, with seven trials. Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for PTCL, followed by Seagen and Takeda.
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
15 MARKETED DRUGS
18 PIPELINE DRUGS
25 KEY UPCOMING EVENTS
26 PROBABILITY OF SUCCESS
27 LICENSING AND ASSET ACQUISITION DEALS
27 Curon Picks Up China-Plus Rights to Rhizen’s Tenalisib
28 REVENUE OPPORTUNITY
29 CLINICAL TRIAL LANDSCAPE
30 Sponsors by status
31 Sponsors by phase
LIST OF FIGURES
12 Figure 1: Trends in incident cases of PTCL, 2017–26
14 Figure 2: Incident cases of PTCL, by age, 2017
18 Figure 3: Overview of pipeline drugs for PTCL in the US
19 Figure 4: Pipeline drugs for PTCL, by company
19 Figure 5: Pipeline drugs for PTCL, by drug type
19 Figure 6: Pipeline drugs for PTCL, by classification
25 Figure 7: Key upcoming events in PTCL
26 Figure 8: Probability of success in the hematologic pipeline
29 Figure 9: Clinical trials in PTCL
29 Figure 10: Top 10 drugs for clinical trials in PTCL
30 Figure 11: Top 10 companies for clinical trials in PTCL
30 Figure 12: Trial locations in PTCL
31 Figure 13: PTCL trials status
32 Figure 14: PTCL trials sponsors, by phase
LIST OF TABLES
11 Table 1: Incident cases of PTCL, 2017–26
13 Table 2: Incident cases of PTCL, by gender, 2017
16 Table 3: Marketed drugs for PTCL
21 Table 4: Pipeline drugs for PTCL in the US
28 Table 5: Historical global sales, by drug ($m), 2016–20
28 Table 6: Forecasted global sales, by drug ($m), 2021–25
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726